Tiansheng Pharmaceutical Group Co

Tiansheng Pharmaceutical Group Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Tiansheng Pharmaceutical Group Co (002872.SZ) as of Oct 21, 2026 is -2.18 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -3.35 % — a change of -34.84% (higher).

EBIT/Assets

-2.18 %

YoY

-34.84%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Tiansheng Pharmaceutical Group Co is 2025 -2.18 % . Operating Income to Assets Ratio (EBIT/Assets) of Tiansheng Pharmaceutical Group Co was 2024 -3.35 % . It decreases by -34.84% higher compared to the previous year.

The Tiansheng Pharmaceutical Group Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
1.30 CNY
Jan 1, 2019
-4.40 CNY
Jan 1, 2020
-13.60 CNY
Jan 1, 2021
-1.95 CNY
Jan 1, 2022
-2.85 CNY
Jan 1, 2023
-3.13 CNY
Jan 1, 2024
-3.35 CNY
Jan 1, 2025
-2.18 CNY
The Tiansheng Pharmaceutical Group Co EBIT/Assets history
YEAREBIT/AssetsYoY
-2.18 %-34.84%
-3.35 %+6.98%
-3.13 %+9.81%
-2.85 %+45.91%
-1.95 %-85.62%
-13.60 %+208.92%
-4.40 %-438.73%
1.30 %-79.16%
6.24 %-22.72%
8.07 %+11.75%
7.22 %+3.92%
6.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tiansheng Pharmaceutical Group Co Stock analysis

What does Tiansheng Pharmaceutical Group Co do? Tiansheng Pharmaceutical Group Co., Ltd. generates revenue through the manufacturing and distribution of pharmaceutical products primarily within the domestic market. Its main products include pediatric lung cough particles, erythromycin enteric-coated capsules, silver ginseng Tongluo capsules, Salvia granules, Shugan Yi spleen granules, compound Ganoderma lucidum granules, Xiangdan injection, Qi and Diabetes tablets, liver capsule, Ling Jing capsule, lungs of nuclear paste, and Shen Qi Yi lung pill. The company focuses on domestic sales, targeting consumers seeking traditional Chinese medicine solutions for respiratory and digestive health. The firm's product portfolio emphasizes traditional Chinese medicine formulations, with specific offerings like Shugan Yi spleen granules for digestive issues and Ling Jing capsule for respiratory conditions. These products are distributed through domestic channels, catering to a market segment that prefers herbal remedies over conventional pharmaceuticals. Tiansheng's revenue stream is derived from the sale of these branded pharmaceutical items to pharmacies and healthcare providers within China. Tiansheng Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tiansheng Pharmaceutical Group Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Tiansheng Pharmaceutical Group Co is -2.18 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Tiansheng Pharmaceutical Group Co changed from -3.35 % to -2.18 %, representing a -34.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Tiansheng Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Tiansheng Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Tiansheng Pharmaceutical Group Co

All Key Metrics — Tiansheng Pharmaceutical Group Co